Tanespimycin (17-AAG)

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

Molecular Weight(MW): 585.69

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Cited by 24 Publications

Int J Biol Sci, 2019, 15(2):312-324

PubMed: 30745823 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):102

PubMed: 30678647 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(5):1051-1060

PubMed: 29440291 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(5):409-423

PubMed: 28052321 ( click the link to review the publication )

Cell, 2017, 170(5):845-859

PubMed: 28823557 ( click the link to review the publication )

Medicinal Chemistry Research, 2016, 10.1007/s00044-016-1553-7

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 51: S659-S660

PubMed: ( click the link to review the publication )

Mol Cancer, 2014, 15:30

PubMed: 24927996 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(10):2237-41

PubMed: 25140805 ( click the link to review the publication )

Exp Gerontol, 2014, 52:55-69

PubMed: 24486130 ( click the link to review the publication )

Insect Mol Biol, 2014, 23(6):720-32

PubMed: 25060629 ( click the link to review the publication )

Julius Maximilians Universit, 2014, Kumari G

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(12):4269-82

PubMed: 24962213 ( click the link to review the publication )

Mol Cell, 2013, 50(3):368-78

PubMed: 23583076 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1830(11):5184-92

PubMed: 23850472 ( click the link to review the publication )

Mol Cell Biol, 2013, 33(12):2375-87

PubMed: 23572559 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2013, 10.1165/rcmb.2013-0214OC

PubMed: 24303801 ( click the link to review the publication )

J Exp Med, 2012, 209(2):259-73

PubMed: 22271575 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1823(4):911-9

PubMed: 22306003 ( click the link to review the publication )

J Biol Chem, 2012, 287(53):44109-20

PubMed: 23144451 ( click the link to review the publication )

Eukaryot Cell, 2012, 11(11):1324-32

PubMed: 22822234 ( click the link to review the publication )

Age (Dordr), 2012, 35(3):549-62

PubMed: 22252435 ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(18):7535-40

PubMed: 21502504 ( click the link to review the publication )

J Nat Prod, 2011, 74(6):1491-9

PubMed: 21553813 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description

Features

Displays very low toxicity toward normal cells.

Targets

HSP90 ^[1]
(Cell-free assay)

5 nM

In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. ^[1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. ^[2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
A549	Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnCTWM2OD1yLkCwNFMxOyEQvF2=	NEHSfZBUSU6JRWK=
IST-MEL1	NEPPOoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIH4Zm5KSzVyPUCuNFAxPDB5IN88US=>	NUjY[WFZW0GQR1XS
NCI-SNU-1	M{LJdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTBwMECyNFch\|ryP	MoDtV2FPT0WU
FADU	MkDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2niV2lEPTB;MD6wNFIxQSEQvF2=	MYTTRW5ITVJ?
C32	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIn5[25KSzVyPUCuNFA{ODRizszN	NIm1VGxUSU6JRWK=
D-566MG	NWS1O5JZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWT3OY1uUUN3ME2wMlAxOzlizszN	MV7TRW5ITVJ?
LXF-289	Mlz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTBwMEC0NVkh\|ryP	MWPTRW5ITVJ?
HGC-27	NYnLfGs6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTBwMEC1NUDPxE1?	NV24V45{W0GQR1XS
RPMI-7951	M{nYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vuOmlEPTB;MD6wNFcyPyEQvF2=	MmL0V2FPT0WU
HSC-3	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTVd40zUUN3ME2wMlAxQTJ7IN88US=>	NEm1VINUSU6JRWK=
MIA-PaCa-2	M17TRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTkeGJMUUN3ME2wMlAyODB7IN88US=>	NGHmT25USU6JRWK=
KS-1	NFr5XIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nubmlEPTB;MD6wNVM2PSEQvF2=	MVrTRW5ITVJ?
CAL-51	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\tT3hKSzVyPUCuNFE1ODVizszN	NXXyeFQ4W0GQR1XS
MDA-MB-361	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPOU\|dHUUN3ME2wMlAyPDl3IN88US=>	NIjUOGJUSU6JRWK=
TI-73	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXvPfJU4UUN3ME2wMlAyPzl4IN88US=>	M1q0cXNCVkeHUh?=
AGS	Mn7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnXTWM2OD1yLkCxPVM5KM7:TR?=	MmD3V2FPT0WU
NCI-H460	MnrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjRUGpKSzVyPUCuNFE6PzRizszN	NGTydHNUSU6JRWK=
A204	NFvaOHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVj2OGpNUUN3ME2wMlAzOjR7IN88US=>	MVnTRW5ITVJ?
CHL-1	NX3NRnRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTBwMEKyOVEh\|ryP	NInwPFFUSU6JRWK=
DU-4475	Mkj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfTVWtKSzVyPUCuNFIzPjFizszN	M3jZcXNCVkeHUh?=
CGTH-W-1	NXT2SFd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LMW2lEPTB;MD6wNlM1QSEQvF2=	NXnrV4NkW0GQR1XS
HCC2218	M3vOb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXOO4ZKSzVyPUCuNFI1QTRizszN	M4rJSXNCVkeHUh?=
A2780	M4W4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLYTWM2OD1yLkCyOVMyKM7:TR?=	M2LmfHNCVkeHUh?=
NCI-H720	M4jBeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\wN2lEPTB;MD6wNlU1PiEQvF2=	M2fMcHNCVkeHUh?=
NCI-N87	M{nnVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nYZmlEPTB;MD6wNlU6OyEQvF2=	MWHTRW5ITVJ?
CHP-212	M4TiXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTBwMEK2Nlgh\|ryP	MWTTRW5ITVJ?
NCI-H23	NXXk[2E3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{KzUmlEPTB;MD6wNlY3PSEQvF2=	MV7TRW5ITVJ?
D-263MG	M{Cwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M332dWlEPTB;MD6wNlc5PiEQvF2=	MlnRV2FPT0WU
ME-180	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mli5TWM2OD1yLkCyPFkyKM7:TR?=	MoLRV2FPT0WU
SW982	MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;VZVZMUUN3ME2wMlAzQTl7IN88US=>	NEPhXFVUSU6JRWK=
OE19	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zsbGlEPTB;MD6wN\|A4PyEQvF2=	MUfTRW5ITVJ?
SK-LU-1	NFjsTWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTBwMEOwPFIh\|ryP	M4rVTnNCVkeHUh?=
H4	NFHHS3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX73W4ZtUUN3ME2wMlA{ODlizszN	NWPNVY9sW0GQR1XS
HT-144	M3zte2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vyOWlEPTB;MD6wN\|A6OyEQvF2=	NIjhUZJUSU6JRWK=
SK-UT-1	MmD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PwZ2lEPTB;MD6wN\|E4QCEQvF2=	MUPTRW5ITVJ?
D-336MG	NU\pV21VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonJTWM2OD1yLkCzN\|A6KM7:TR?=	NE\6ZodUSU6JRWK=
MDA-MB-175-VII	Mm\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTBwMEOzOVQh\|ryP	NXz5RVVNW0GQR1XS
GAMG	MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jRemlEPTB;MD6wN\|Q{PSEQvF2=	MmDTV2FPT0WU
CP50-MEL-B	MlHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV2z[FJHUUN3ME2wMlA{PDVizszN	Mm\SV2FPT0WU
OVCAR-5	Mnn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvGdG93UUN3ME2wMlA{PDhizszN	MVrTRW5ITVJ?
SK-MES-1	MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTBwMEO2NFYh\|ryP	NGPGN5BUSU6JRWK=
VM-CUB-1	M{XrNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPsb5BPUUN3ME2wMlA{PjV5IN88US=>	NHHTS5pUSU6JRWK=
WM-115	NYfDelBwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEK3T5JKSzVyPUCuNFM4PjJizszN	NEfxXYRUSU6JRWK=
DSH1	NGHFPJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Moj1TWM2OD1yLkCzPFA4KM7:TR?=	NXm0Ro17W0GQR1XS
Becker	NWXPZWRXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHwSWpKSzVyPUCuNFM5QDVizszN	M{O4RXNCVkeHUh?=
SW962	NYHP[lhET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTBwMEO5OFUh\|ryP	MW\TRW5ITVJ?
TYK-nu	NInHfWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITpZYZKSzVyPUCuNFM6QDVizszN	NH;SWplUSU6JRWK=
HO-1-N-1	MnLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTBwMESwNlEh\|ryP	M{DIUnNCVkeHUh?=
T98G	NF3HVZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHjbWVyUUN3ME2wMlA1OTB\|IN88US=>	MlH4V2FPT0WU
ACN	NFnhUlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DjcmlEPTB;MD6wOFE3OiEQvF2=	NH\XeG5USU6JRWK=
SW780	NWewTYpjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTDNWtJUUN3ME2wMlA1OjB\|IN88US=>	NXTE[IJFW0GQR1XS
Detroit562	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\iR2lEPTB;MD6wOFI{QSEQvF2=	MXrTRW5ITVJ?
BB49-HNC	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2GzPGlEPTB;MD6wOFI1OyEQvF2=	NELCUXlUSU6JRWK=
HN	M3\ENmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYn4TJZEUUN3ME2wMlA1Ojd{IN88US=>	MnTMV2FPT0WU
H9	NHXVXlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLRU3dKSzVyPUCuNFQ{PzFizszN	MUDTRW5ITVJ?
VA-ES-BJ	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XUT2lEPTB;MD6wOFQ1PyEQvF2=	M4DyR3NCVkeHUh?=
MEL-JUSO	NGnxTFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7Zd2lKSzVyPUCuNFQ1PzVizszN	NVK1Z5FyW0GQR1XS
BT-474	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwMES1JO69VQ>?	MYPTRW5ITVJ?
CaR-1	M1f5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnFTWM2OD1yLkC0OVQ6KM7:TR?=	MlvtV2FPT0WU
PSN1	NHS4XGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTBwMES2NFMh\|ryP	NFfyWmtUSU6JRWK=
KYSE-510	Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rHTWlEPTB;MD6wOFY1QSEQvF2=	M4fIS3NCVkeHUh?=
KP-4	MlrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XHbGlEPTB;MD6wOFc2OyEQvF2=	MoTxV2FPT0WU
KYSE-410	M2jP[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTBwMES3O\|Ih\|ryP	MmjxV2FPT0WU
G-402	M3;WR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTBwMES3PFkh\|ryP	NW\lfVRWW0GQR1XS
DOK	MlvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17wc2lEPTB;MD6wOFkxOiEQvF2=	MoTIV2FPT0WU
COR-L88	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1:y[2lEPTB;MD6wOFkyOiEQvF2=	MXnTRW5ITVJ?
SKG-IIIa	M{f6WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTBwMES5PFYh\|ryP	MlHxV2FPT0WU
AN3-CA	M{jyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\XOo1KSzVyPUCuNFUh\|ryP	NWmzV2h[W0GQR1XS
SW48	NFHQOnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1KwcmlEPTB;MD6wOVA{QSEQvF2=	M1THcXNCVkeHUh?=
YKG-1	NXvlXVdGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mki0TWM2OD1yLkC1NFcyKM7:TR?=	MkLSV2FPT0WU
KYSE-150	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3xWFdKSzVyPUCuNFUzOzVizszN	NF73PW9USU6JRWK=
HuO-3N1	MlW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTBwMEWyN\|ch\|ryP	MXzTRW5ITVJ?
LB1047-RCC	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHOTWM2OD1yLkC1Nlk3KM7:TR?=	NIjSdm5USU6JRWK=
NCI-H2030	MoSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\neI9HUUN3ME2wMlA2PDF2IN88US=>	MWnTRW5ITVJ?
YH-13	NYLOR3M3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TqT2lEPTB;MD6wOVczOiEQvF2=	MnP6V2FPT0WU
5637	NU\ONohET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXvTWM2OD1yLkC1O\|Qh\|ryP	MlHrV2FPT0WU
LOXIMVI	NF[wSGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4i5RWlEPTB;MD6wOVg4OiEQvF2=	NV33bndWW0GQR1XS
GT3TKB	NEXOUohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoD0TWM2OD1yLkC1PVQzKM7:TR?=	NV;Sb\|ZQW0GQR1XS
TCCSUP	NFjSUJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nIPGlEPTB;MD6wOVk3PCEQvF2=	MVvTRW5ITVJ?
EPLC-272H	NGL1PJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zNNmlEPTB;MD6wOlIxPSEQvF2=	MnS0V2FPT0WU
LU-99A	NWTGXGY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTBwME[yN\|ch\|ryP	MoqyV2FPT0WU
NCI-H1755	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LVUmlEPTB;MD6wOlM1OSEQvF2=	MlPsV2FPT0WU
KM12	M1:xNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrkTWM2OD1yLkC2N\|Q5KM7:TR?=	MWjTRW5ITVJ?
SF295	MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHGyfHVKSzVyPUCuNFY1PTJizszN	MW\TRW5ITVJ?
MZ2-MEL	NILXSFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\ve2lEPTB;MD6wOlU2OyEQvF2=	M3rZU3NCVkeHUh?=
HEC-1	MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLJflN7UUN3ME2wMlA3PTh6IN88US=>	MnfvV2FPT0WU
SW684	MojjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{frN2lEPTB;MD6wOlU6OSEQvF2=	M1rS[nNCVkeHUh?=
SF539	NIn3V\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTBwME[2PFEh\|ryP	NHLheo5USU6JRWK=
GMS-10	MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTBwME[2PVkh\|ryP	M3[zVnNCVkeHUh?=
MV-4-11	M3vyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\QWWlEPTB;MD6wOlgxOyEQvF2=	Mk\lV2FPT0WU
HT-29	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTBwME[5NVkh\|ryP	MkH2V2FPT0WU
23132-87	NUjucJZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTBwME[5OUDPxE1?	NXLFT5VJW0GQR1XS
SW620	M4rqTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTBwMEewNlYh\|ryP	NXfneIx6W0GQR1XS
HCC1806	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\CUVJKSzVyPUCuNFcyOzFizszN	MUDTRW5ITVJ?
Hs-578-T	NIK5elFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;kdGlEPTB;MD6wO\|IxQCEQvF2=	MVrTRW5ITVJ?
A2058	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHnTWM2OD1yLkC3NlI5KM7:TR?=	M1rQbXNCVkeHUh?=
MEL-HO	M2DBZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4K5ZmlEPTB;MD6wO\|I2PSEQvF2=	NWf6UldZW0GQR1XS
HCC2998	M4q3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTBwMEezOFch\|ryP	M{\WOHNCVkeHUh?=
HuO9	MnnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2WzTmlEPTB;MD6wO\|U5QSEQvF2=	NEDne\|VUSU6JRWK=
CAL-39	MlPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPkcXlMUUN3ME2wMlA4PzZ4IN88US=>	M{jDVHNCVkeHUh?=
M14	NXPaPW5jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPnOGpKSzVyPUCuNFc6OTNizszN	NIDEVXdUSU6JRWK=
BFTC-909	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTBwMEe5Olkh\|ryP	M1PQZ3NCVkeHUh?=
TE-11	M3m5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\5[Y5KSzVyPUCuNFc6QTZizszN	NX;RS5NtW0GQR1XS
TGBC1TKB	MkjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3q1b2lEPTB;MD6wPFA1OyEQvF2=	NUTvPY13W0GQR1XS
L-363	NXLOZoxQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{Tuc2lEPTB;MD6wPFIxPiEQvF2=	Mo\DV2FPT0WU
A431	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXe2fVMzUUN3ME2wMlA5OjFizszN	M4XvcXNCVkeHUh?=
MKN45	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDV[oxKSzVyPUCuNFgzOTlizszN	NUjCS4dtW0GQR1XS
HT-1080	MkjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTBwMEi0N\|kh\|ryP	M4C1dHNCVkeHUh?=
OVCAR-8	M4mxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTBwMEi2NlIh\|ryP	M3G5VHNCVkeHUh?=
LCLC-97TM1	NWDn[lJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zTWWlEPTB;MD6wPFczQCEQvF2=	MUnTRW5ITVJ?
M059J	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETabnRKSzVyPUCuNFkxOjdizszN	M{jrOXNCVkeHUh?=
SK-MEL-2	NYToNZA1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHQOG52UUN3ME2wMlA6ODZizszN	MkDDV2FPT0WU
TE-1	NX62c2k2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTBwMEmyNFQh\|ryP	MmrLV2FPT0WU
KYSE-180	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3X3SGlEPTB;MD6wPVI3OiEQvF2=	M4TURXNCVkeHUh?=
D-247MG	NHzxWoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXaTWM2OD1yLkC5OFU2KM7:TR?=	M3;aVHNCVkeHUh?=
8-MG-BA	NETQU4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LLVWlEPTB;MD6wPVQ4OiEQvF2=	NYSxUFRSW0GQR1XS
NCI-H1792	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnUUI1OUUN3ME2wMlA6PjF6IN88US=>	M3S5T3NCVkeHUh?=
MCF7	NFPqTINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkmyTWM2OD1yLkC5Olc4KM7:TR?=	M1PqcHNCVkeHUh?=
NCI-H2122	NEW5epRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LuXGlEPTB;MD6wPVc1PSEQvF2=	MmLTV2FPT0WU
EFO-27	MknUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTBwMEm5PVch\|ryP	NXnKcFRZW0GQR1XS
LB2241-RCC	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTBwMUCwOVQh\|ryP	NXfhTnhZW0GQR1XS
SN12C	NVfhTZVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHSwNVhKSzVyPUCuNVAyODdizszN	NGjxOndUSU6JRWK=
A498	M37zVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLRdWdKSzVyPUCuNVAyQCEQvF2=	MonYV2FPT0WU
PANC-03-27	NVzvcHg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnlTlNEUUN3ME2wMlExOjh4IN88US=>	NFjnTYJUSU6JRWK=
NCI-H1581	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTBwMUCyPUDPxE1?	NYDnT4Q3W0GQR1XS
U-87-MG	M1vj[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDVemR2UUN3ME2wMlExOzB5IN88US=>	M2\ke3NCVkeHUh?=
G-401	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDRR3BMUUN3ME2wMlExOzV\|IN88US=>	MYHTRW5ITVJ?
SiHa	NHX4TJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmiyTWM2OD1yLkGwOFg3KM7:TR?=	NFTh[VdUSU6JRWK=
U251	M1nOWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;JdW9OUUN3ME2wMlExPTJ3IN88US=>	MWjTRW5ITVJ?
MMAC-SF	NYfrVJI3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXoTWM2OD1yLkGwOVMyKM7:TR?=	MVrTRW5ITVJ?
BB65-RCC	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTBwMUC1OVQh\|ryP	NE\XWmdUSU6JRWK=
NKM-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnjSlhKSzVyPUCuNVA3PjZizszN	MVjTRW5ITVJ?
HD-MY-Z	NIHBV\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFj6U4dKSzVyPUCuNVA5PzNizszN	NGCy[lZUSU6JRWK=
TGBC11TKB	NHjLW5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\pTZhDUUN3ME2wMlExQTB\|IN88US=>	NUfEeJVsW0GQR1XS
COLO-679	NXjCe25FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHe0cnhKSzVyPUCuNVEzOTFizszN	MlPhV2FPT0WU
TE-8	M2LPWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1y2SGlEPTB;MD6xNVI3PCEQvF2=	NIfIV2tUSU6JRWK=
SK-MEL-28	NYj1fYR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jzfmlEPTB;MD6xNVMzOSEQvF2=	MULTRW5ITVJ?
SH-4	NVKwXFlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvKTWM2OD1yLkGxN\|U3KM7:TR?=	MVPTRW5ITVJ?
KALS-1	NY\EUWdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3qxTmlEPTB;MD6xNVM6OyEQvF2=	MWrTRW5ITVJ?
RKO	MlTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoH1TWM2OD1yLkGxO\|Y1KM7:TR?=	NHm1XpJUSU6JRWK=
OMC-1	NXz2PYt2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4D3dGlEPTB;MD6xNVc6PyEQvF2=	M3qycXNCVkeHUh?=
BT-549	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTBwMUG3PVkh\|ryP	M1XIbnNCVkeHUh?=
NCI-H28	M{DPZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXrcJRKSzVyPUCuNVE5OTdizszN	NIjqcHFUSU6JRWK=
RXF393	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTBwMUG5PFIh\|ryP	NFXRW4tUSU6JRWK=
COLO-829	NWXZVnM4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPNTWM2OD1yLkGyNFA2KM7:TR?=	NUHUfYF1W0GQR1XS
HMV-II	MlHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\1TWM2OD1yLkGyNFIh\|ryP	M4\0UHNCVkeHUh?=
SW1990	NFLrdGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUm2N3ozUUN3ME2wMlEzOTV5IN88US=>	M2TVd3NCVkeHUh?=
NCI-H1437	NWj1OoFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HjZ2lEPTB;MD6xNlE2PyEQvF2=	MkjLV2FPT0WU
SNB75	M3X2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13LSGlEPTB;MD6xNlE3QSEQvF2=	MX\TRW5ITVJ?
EW-3	MnrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlr6TWM2OD1yLkGyOlYyKM7:TR?=	MYTTRW5ITVJ?
SAS	MmTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWe3SlRuUUN3ME2wMlEzPjlizszN	Ml\YV2FPT0WU
NCI-H1666	M1vWRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWr2c4c{UUN3ME2wMlEzPzd2IN88US=>	MUDTRW5ITVJ?
A375	NVuwVYt1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjJUmZKSzVyPUCuNVI4PzhizszN	NHzrdYlUSU6JRWK=
CAMA-1	Mn7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7afI1KSzVyPUCuNVI6OjRizszN	MkXqV2FPT0WU
HuP-T4	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3VTWM2OD1yLkGyPVQ{KM7:TR?=	NW\VVolNW0GQR1XS
NCI-H292	NILRTpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTBwMUOxNUDPxE1?	Mkn0V2FPT0WU
PC-14	M2\aUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnSXHdLUUN3ME2wMlE{OjFzIN88US=>	Mk[3V2FPT0WU
BPH-1	Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHYTWM2OD1yLkGzOFEh\|ryP	NVXtcHZFW0GQR1XS
GAK	NXOwW2hWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7tdVNtUUN3ME2wMlE{PTZ5IN88US=>	M2LZbXNCVkeHUh?=
VMRC-RCZ	M3y3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkGxTWM2OD1yLkGzO\|YzKM7:TR?=	NGjIOotUSU6JRWK=
SK-MEL-24	MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljBTWM2OD1yLkGzPFch\|ryP	Mni5V2FPT0WU
LB831-BLC	Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF60dHVKSzVyPUCuNVM5QDNizszN	MXvTRW5ITVJ?
NCI-H2452	NHHDO4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1:4dWlEPTB;MD6xN\|k2PiEQvF2=	NWCybFljW0GQR1XS
RT-112	M1m0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnj6TWM2OD1yLkG0NFM2KM7:TR?=	MlLlV2FPT0WU
GP5d	NYnQWWI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTBwMUSxNFQh\|ryP	Mmn3V2FPT0WU
LC-2-ad	Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTBwMUSxNlEh\|ryP	M3nKZ3NCVkeHUh?=
MPP-89	M4D1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLvSo1KSzVyPUCuNVQyOjVizszN	MWHTRW5ITVJ?
NUGC-3	MlLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTBwMUS0O\|gh\|ryP	NFv2d21USU6JRWK=
GI-1	NWPiTI5LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjodFJqUUN3ME2wMlE1PTV6IN88US=>	MYDTRW5ITVJ?
HCC1419	NIXp[XNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlW5TWM2OD1yLkG0OVc3KM7:TR?=	NXzrTWh2W0GQR1XS
SW1573	MkT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTBwMUS3OVgh\|ryP	MoLSV2FPT0WU
NCI-H2347	M4PwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI[xPG9KSzVyPUCuNVQ5OzlizszN	MmrEV2FPT0WU
Mewo	NVWzb3ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nPcmlEPTB;MD6xOFg5QSEQvF2=	MnXuV2FPT0WU
639-V	NHHLO4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTBwMUWwNVMh\|ryP	MX7TRW5ITVJ?
AsPC-1	NG[2NYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTpTWM2OD1yLkG1NlI2KM7:TR?=	NF3aSnRUSU6JRWK=
NCI-H1648	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;kV5VKSzVyPUCuNVUzOzJizszN	MWTTRW5ITVJ?
786-0	Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILJOodKSzVyPUCuNVU{QDFizszN	MVXTRW5ITVJ?
ETK-1	NYn1VG9iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDWfFFKSzVyPUCuNVU6KM7:TR?=	M2HndHNCVkeHUh?=
BxPC-3	NWrPOYpyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV7JR\|UxRTBwMUW5OlYh\|ryP	M2TudnNCVkeHUh?=
CAL-62	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTBwMU[xOlkh\|ryP	NFHabotUSU6JRWK=
HCC1937	NYrORpdnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XvUmlEPTB;MD6xOlI4PSEQvF2=	NYXsdZB[W0GQR1XS
NCI-H1299	MkDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1H1[GlEPTB;MD6xOlI5PSEQvF2=	NUnpOXpCW0GQR1XS
SW1088	MnvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH3pSGxKSzVyPUCuNVY1OTNizszN	M1Prd3NCVkeHUh?=
FTC-133	NWq5[VNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPr[JNKSzVyPUCuNVY2PCEQvF2=	NWntblN3W0GQR1XS
OC-314	M4PyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;tVGlEPTB;MD6xOlY6KM7:TR?=	MkLNV2FPT0WU
SCC-9	MkL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTBwMU[3NVYh\|ryP	NYrtUYV2W0GQR1XS
HT-1376	M{H1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4H1WmlEPTB;MD6xOlk{PiEQvF2=	MVXTRW5ITVJ?
U-2-OS	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLZOGd{UUN3ME2wMlE4OTd\|IN88US=>	NFzQTo5USU6JRWK=
COLO-824	MoLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\l[oxKSzVyPUCuNVczQTRizszN	M{LHWnNCVkeHUh?=
BB30-HNC	NInnU5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfITWM2OD1yLkG3N\|Mh\|ryP	M{nk[nNCVkeHUh?=
NCI-H2087	Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvpO3NxUUN3ME2wMlE4OzZ6IN88US=>	Mk\mV2FPT0WU
NCI-H2170	MoHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEH2b2FKSzVyPUCuNVc2OzZizszN	NILhflNUSU6JRWK=
SK-OV-3	NEnpN2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLUd\|M6UUN3ME2wMlE4PTdzIN88US=>	MXrTRW5ITVJ?
MZ7-mel	M3:3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIT5[JVKSzVyPUCuNVc3PDlizszN	NEDuRlBUSU6JRWK=
NCI-H650	NWHpXWVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\UW2lEPTB;MD6xO\|Y5OiEQvF2=	M{DsfHNCVkeHUh?=
KOSC-2	NWfsSWlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXG1PJZGUUN3ME2wMlE4PzN2IN88US=>	NX\pTWxjW0GQR1XS
SCC-4	NXrMNXZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHPUm9KSzVyPUCuNVc4PzdizszN	NHL6cFZUSU6JRWK=
MDA-MB-157	NUHReXdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TEPWlEPTB;MD6xPFA5OiEQvF2=	NXHtNFZuW0GQR1XS
KYSE-520	M1PrTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHNTWM2OD1yLkG4NkDPxE1?	MULTRW5ITVJ?
LK-2	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVOydFNmUUN3ME2wMlE5OzB\|IN88US=>	NHOwd4hUSU6JRWK=
KNS-81-FD	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTBwMUizPVQh\|ryP	MXzTRW5ITVJ?
IGROV-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DHNmlEPTB;MD6xPFQ1OyEQvF2=	MV;TRW5ITVJ?
DEL	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTBwMUi0OUDPxE1?	NF\tXGZUSU6JRWK=
NCI-H1395	NELTTVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnNTWM2OD1yLkG4OlgzKM7:TR?=	M1HjVnNCVkeHUh?=
JEG-3	M1r2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnnN2lnUUN3ME2wMlE5PzB3IN88US=>	M2W3bXNCVkeHUh?=
BCPAP	NH7mRnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13zPGlEPTB;MD6xPFg4OiEQvF2=	M4LuW3NCVkeHUh?=
CAL-27	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTBwMUmwNlIh\|ryP	M3;JTnNCVkeHUh?=
RD	M3PtXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLKTWM2OD1yLkG5NVE{KM7:TR?=	M3;B[HNCVkeHUh?=
RVH-421	NV\RZm1TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW[5VGxuUUN3ME2wMlE6OTF4IN88US=>	M3\tWXNCVkeHUh?=
Capan-2	Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvSTWM2OD1yLkG5NlU3KM7:TR?=	NFHlOnNUSU6JRWK=
COLO-680N	MoHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPSVmNzUUN3ME2wMlE6OzZ2IN88US=>	Mke5V2FPT0WU
NCI-H1650	NYHY[5RrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnSeph6UUN3ME2wMlIxODV5IN88US=>	MWTTRW5ITVJ?
SBC-5	M3;IN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\SZ3FwUUN3ME2wMlIxOTF6IN88US=>	M3v2fnNCVkeHUh?=
U031	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTBwMkC1OFch\|ryP	NIrwfI1USU6JRWK=
S-117	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;XO4JKSzVyPUCuNlA2PjRizszN	NGDhRnpUSU6JRWK=
DoTc2-4510	M1fu[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTNTWM2OD1yLkKwO\|Y6KM7:TR?=	MYDTRW5ITVJ?
AM-38	MmriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLZTWM2OD1yLkKwPFQ5KM7:TR?=	M3jlT3NCVkeHUh?=
A172	M1XUR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXT4UYRQUUN3ME2wMlIyODJ{IN88US=>	NI\KXVlUSU6JRWK=
HPAF-II	NILLNXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXFS5V{UUN3ME2wMlIyOjZ2IN88US=>	Ml;sV2FPT0WU
769-P	NXjjRXNWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LpemlEPTB;MD6yNVI5KM7:TR?=	NI\jZ4NUSU6JRWK=
MFE-280	M3zZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTBwMkGyPVgh\|ryP	NYPsZXNSW0GQR1XS
TE-9	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljDTWM2OD1yLkKxO\|g3KM7:TR?=	MUfTRW5ITVJ?
C2BBe1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXuTWM2OD1yLkKyNVkh\|ryP	NVzVWZQ3W0GQR1XS
EoL-1-cell	MnS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\TZ45KSzVyPUCuNlIzODNizszN	NHPnOXpUSU6JRWK=
G-361	M13WbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELjTItKSzVyPUCuNlI3QDJizszN	M2DkdXNCVkeHUh?=
KYSE-270	MkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTBwMkOwPFQh\|ryP	MYDTRW5ITVJ?
TK10	NUKyS5lpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDnTWM2OD1yLkKzNVE4KM7:TR?=	M1zzW3NCVkeHUh?=
ML-2	NEHqRllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXwU45KSzVyPUCuNlMyOTlizszN	NGXIZZVUSU6JRWK=
MHH-ES-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWHoOY9sUUN3ME2wMlI{PjhzIN88US=>	MVnTRW5ITVJ?
BHY	MnqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\OO2lEPTB;MD6yN\|Y6OSEQvF2=	MYfTRW5ITVJ?
LS-513	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jPUGlEPTB;MD6yN\|k3OSEQvF2=	M16yb3NCVkeHUh?=
COLO-678	NGHYblNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjJ[\|VLUUN3ME2wMlI1ODR2IN88US=>	M4\3fnNCVkeHUh?=
NCI-H747	M4[xdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWn4TW1uUUN3ME2wMlI1OTZ7IN88US=>	M4LjSXNCVkeHUh?=
K5	M3vTR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3n0dmlEPTB;MD6yOFM5KM7:TR?=	NVLsenZIW0GQR1XS
OS-RC-2	NHrzZ\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmToTWM2OD1yLkK0OVA6KM7:TR?=	MlXpV2FPT0WU
KINGS-1	M3rs[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTBwMkS1Nlkh\|ryP	MkTVV2FPT0WU
SCC-25	MmLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HKe2lEPTB;MD6yOFU3OyEQvF2=	NELSSGdUSU6JRWK=
CAPAN-1	NW\NeGNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHflT\|NKSzVyPUCuNlQ4QDNizszN	M2HmbnNCVkeHUh?=
ESS-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPhbldKSzVyPUCuNlQ5ODVizszN	MWrTRW5ITVJ?
TE-6	MlnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{TvT2lEPTB;MD6yOVc2KM7:TR?=	M3jhU3NCVkeHUh?=
LB2518-MEL	NUP5SmdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIe5U4tKSzVyPUCuNlU4PzdizszN	MljjV2FPT0WU
COLO-800	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvnTWM2OD1yLkK1PFEzKM7:TR?=	MVXTRW5ITVJ?
LU-134-A	Mn3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3Lie2lEPTB;MD6yOlE{PiEQvF2=	M2nQNXNCVkeHUh?=
NCI-H1155	M2LHPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTBwMk[xOlIh\|ryP	NIe0UIlUSU6JRWK=
MFM-223	NIr1TGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTaeZcyUUN3ME2wMlI3OzZ\|IN88US=>	NHXMSmRUSU6JRWK=
HTC-C3	NHThO4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTmTWM2OD1yLkK2OVA3KM7:TR?=	M1jtV3NCVkeHUh?=
HCT-116	NUfCXXNDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFG4N5pKSzVyPUCuNlY2QTlizszN	MmG3V2FPT0WU
Ca-Ski	M{\xW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPUTWM2OD1yLkK2Olc5KM7:TR?=	NWf0OIhCW0GQR1XS
SBC-1	M2SwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3X1XGlEPTB;MD6yOlc1OiEQvF2=	NVjPb4FmW0GQR1XS
NB69	MnrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDzNVlKSzVyPUCuNlcxQDdizszN	NV\oeoduW0GQR1XS
J82	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\aW5RpUUN3ME2wMlI4OjZ3IN88US=>	M2nOPHNCVkeHUh?=
U-118-MG	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zhT2lEPTB;MD6yO\|U4QSEQvF2=	MUTTRW5ITVJ?
NCI-H1355	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fp[WlEPTB;MD6yPFA4PCEQvF2=	MXLTRW5ITVJ?
NCI-H1048	NVjx[VNYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDDTWM2OD1yLkK4PVU3KM7:TR?=	MoqxV2FPT0WU
SW954	M2LDWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;mNmdKSzVyPUCuNlkzOjdizszN	M{i4V3NCVkeHUh?=
NMC-G1	NX[3RYZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\zcYhsUUN3ME2wMlI6Ojd5IN88US=>	MXPTRW5ITVJ?
SW1710	M4PTZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XpSmlEPTB;MD6yPVQ6PCEQvF2=	MUTTRW5ITVJ?
KY821	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4K2ZmlEPTB;MD6yPVg4OiEQvF2=	NFPuWIlUSU6JRWK=
HCC38	NY\jc4FqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fVW2lEPTB;MD6zNFA4QCEQvF2=	NUntSnNzW0GQR1XS
NCI-SNU-5	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnWzTWM2OD1yLkOwOVQh\|ryP	MmDPV2FPT0WU
ES8	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfNTWM2OD1yLkOwO\|g1KM7:TR?=	NXjwZ49mW0GQR1XS
COLO-792	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWD4VXlFUUN3ME2wMlMyOjVzIN88US=>	Ml7lV2FPT0WU
BFTC-905	Mne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTBwM{G1NlEh\|ryP	NIHoS3lUSU6JRWK=
ChaGo-K-1	NFS2VGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTBwM{G3NVUh\|ryP	NXjRUHN[W0GQR1XS
Daoy	M1jXVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XXOGlEPTB;MD6zNVczOyEQvF2=	MmLKV2FPT0WU
SJSA-1	MnPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTBwM{G4OFch\|ryP	M2\ZVXNCVkeHUh?=
KNS-62	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HWRWlEPTB;MD6zNlA5QCEQvF2=	NFPh[\|JUSU6JRWK=
CAKI-1	NFjPUG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\VR29KSzVyPUCuN\|IyOTFizszN	NFr3[XJUSU6JRWK=
UACC-62	MoLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmr5TWM2OD1yLkOyNlI4KM7:TR?=	NYjMOZN7W0GQR1XS
HuCCT1	NUHxOJlUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTBwM{KyPFMh\|ryP	M{LWdXNCVkeHUh?=
CTB-1	Ml;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\lXGlEPTB;MD6zNlc2OyEQvF2=	MlnqV2FPT0WU
NTERA-S-cl-D1	M3HuSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXoTWM2OD1yLkOyPFM3KM7:TR?=	MUDTRW5ITVJ?
T-24	MljzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlz0TWM2OD1yLkOzNVU6KM7:TR?=	M3jSfXNCVkeHUh?=
KYSE-70	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInCPW5KSzVyPUCuN\|MzQDNizszN	NW[2O3BrW0GQR1XS
SW626	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXBTWM2OD1yLkOzOVMzKM7:TR?=	M3nxc3NCVkeHUh?=
LB996-RCC	M4nsNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;MN2RKSzVyPUCuN\|M3OTlizszN	NInnWJNUSU6JRWK=
DMS-273	NYW5Vm1zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fod2lEPTB;MD6zN\|kyPiEQvF2=	NXrmeFRDW0GQR1XS
SW1783	NIjxUWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nJWmlEPTB;MD6zN\|k6PyEQvF2=	NInJU3NUSU6JRWK=
KU812	NIW5b3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLZTJhHUUN3ME2wMlM1ODN6IN88US=>	M2fRdnNCVkeHUh?=
HSC-2	Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2S5R2lEPTB;MD6zOFA2OyEQvF2=	MUTTRW5ITVJ?
A3-KAW	NFGwZnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTBwM{SxOlIh\|ryP	NHn6VY5USU6JRWK=
COLO-684	M{C5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjRUIxOUUN3ME2wMlM1PTBzIN88US=>	MnmyV2FPT0WU
NCI-H2405	M1XuVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XjfGlEPTB;MD6zOFY{OSEQvF2=	NG[5RYxUSU6JRWK=
NCI-H2228	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;UPGlEPTB;MD6zOVM2PyEQvF2=	MmLQV2FPT0WU
NB13	NVzheGJRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUL2cWxuUUN3ME2wMlM3QDJ7IN88US=>	Mm[yV2FPT0WU
no-11	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jzVGlEPTB;MD6zOlk2KM7:TR?=	Mle1V2FPT0WU
DK-MG	M4rxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTBwM{exPFgh\|ryP	NUDSUotrW0GQR1XS
NBsusSR	M{PhXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\L[3NKSzVyPUCuN\|czQDVizszN	NX3LfnNNW0GQR1XS
KP-N-YS	NF\xSGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LpR2lEPTB;MD6zO\|Q3OyEQvF2=	MmLmV2FPT0WU
CFPAC-1	NEftVmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPkNXJIUUN3ME2wMlM4PTF6IN88US=>	MVfTRW5ITVJ?
KARPAS-45	M{\INWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1K4ZWlEPTB;MD6zO\|g3OiEQvF2=	MlGwV2FPT0WU
NCI-H1793	NVTlW2tnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\vTWM2OD1yLkO4OVEh\|ryP	MWPTRW5ITVJ?
HCE-T	NFT5cotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfje2ZuUUN3ME2wMlM5PjB\|IN88US=>	Ml\WV2FPT0WU
NCI-H520	M1y5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjKTWM2OD1yLkO4O\|A{KM7:TR?=	NVOxWnFwW0GQR1XS
HCC2157	NXS1V3R{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XTNmlEPTB;MD6zPFc5OSEQvF2=	M{TNenNCVkeHUh?=
EW-18	Ml25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjh[XVKSzVyPUCuN\|g6PDFizszN	MVzTRW5ITVJ?
RO82-W-1	M4\Ldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTBwM{m2PVkh\|ryP	M2jvTXNCVkeHUh?=
HuP-T3	M4fwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDLTWM2OD1yLkSwNVQ{KM7:TR?=	NULiWZhnW0GQR1XS
PANC-10-05	NHLxW29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF6xfnhKSzVyPUCuOFEyPyEQvF2=	NEn0dYtUSU6JRWK=
NCI-H1703	NHrCZnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkDVTWM2OD1yLkSxOFQ3KM7:TR?=	M1TBTHNCVkeHUh?=
TE-10	M1O2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzJTWM2OD1yLkSxOFQ4KM7:TR?=	NG\qVpdUSU6JRWK=
HOS	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWHIU5Z4UUN3ME2wMlQyPjh{IN88US=>	MULTRW5ITVJ?
LN-405	M3TP[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTBwNEG2PFch\|ryP	NFrZXpBUSU6JRWK=
A427	NVrnSZNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLqTWM2OD1yLkSxPVgyKM7:TR?=	NYjYRllRW0GQR1XS
CAL-12T	MmPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnBTWM2OD1yLkSyO\|gh\|ryP	NVHoT2k3W0GQR1XS
SW756	NIewUYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1T4dGlEPTB;MD60OFE5OyEQvF2=	NFnM[G9USU6JRWK=
YAPC	MlTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHwZXQ{UUN3ME2wMlQ2ODhizszN	M2e1enNCVkeHUh?=
GOTO	NInCbYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnriTWM2OD1yLkS1NVYh\|ryP	M2noXHNCVkeHUh?=
C3A	NGHQNo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfUVGlKSzVyPUCuOFU1OzdizszN	MnTOV2FPT0WU
UM-UC-3	M3njUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTBwNEW0O{DPxE1?	Ml7ZV2FPT0WU
NCI-H1573	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NITwZoVKSzVyPUCuOFU2PjlizszN	MnfBV2FPT0WU
LS-411N	MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlO4TWM2OD1yLkS2OVI4KM7:TR?=	MlvjV2FPT0WU
COR-L23	M4\MeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHrbVFHUUN3ME2wMlQ3PzZ2IN88US=>	MkS0V2FPT0WU
HCE-4	M4r3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGOyU2JKSzVyPUCuOFc1PDZizszN	NIq2fWlUSU6JRWK=
NCI-H2291	NXz1dng2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnUepBmUUN3ME2wMlQ4QDl4IN88US=>	NUf4S5BzW0GQR1XS
A101D	NGDOT3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDYTWM2OD1yLkS4NFU{KM7:TR?=	MU\TRW5ITVJ?
HT-3	NVvzXJhIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWL2fHlqUUN3ME2wMlQ5OjF5IN88US=>	Mkf0V2FPT0WU
HOP-62	NX:4flY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2jBOWlEPTB;MD60PVg3PSEQvF2=	MWfTRW5ITVJ?
PC-3	NIS3cYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;aTWM2OD1yLkWxOVA4KM7:TR?=	M1LrUnNCVkeHUh?=
CTV-1	NVjwTYRFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;KdINRUUN3ME2wMlUzPjZ7IN88US=>	NGr2WZlUSU6JRWK=
PANC-08-13	Ml2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1S4VmlEPTB;MD61N\|E4PyEQvF2=	Mn75V2FPT0WU
CAL-120	M1\FSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnm2TWM2OD1yLkWzN\|k6KM7:TR?=	NYDRSXVOW0GQR1XS
UMC-11	M17Gdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTBwNUWyN\|Qh\|ryP	MmHkV2FPT0WU
MSTO-211H	NYO0Z2R4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUSwSYtwUUN3ME2wMlU2PzZ{IN88US=>	NF6xUGVUSU6JRWK=
NCI-H2126	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4[2bWlEPTB;MD61OlgyPSEQvF2=	NEOyOlFUSU6JRWK=
SNU-C2B	NFi4WJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jpdGlEPTB;MD61O\|k4PyEQvF2=	MUnTRW5ITVJ?
DBTRG-05MG	NWXvO4x3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTic5gyUUN3ME2wMlU5ODV\|IN88US=>	NH3YfIhUSU6JRWK=
MKN1	Mo\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTBwNUi3PFMh\|ryP	NHqyUIhUSU6JRWK=
ES3	Mn3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonnTWM2OD1yLkW5NVI1KM7:TR?=	NGTjZ49USU6JRWK=
OVCAR-3	MljWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXhNYJKSzVyPUCuOVk{PDFizszN	MUDTRW5ITVJ?
ACHN	NFy2RpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\WWoFKSzVyPUCuOlA2PjlizszN	M{nZNXNCVkeHUh?=
SW872	NEW4eHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTBwNkC3OlMh\|ryP	NXPCdnNTW0GQR1XS
CP66-MEL	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;JUIFxUUN3ME2wMlYxQTZ7IN88US=>	M2PBR3NCVkeHUh?=
NCI-H661	Mn73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTBwNkGxNFQh\|ryP	MkO1V2FPT0WU
UACC-893	MkK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\lTWM2OD1yLk[zOlgyKM7:TR?=	NUHsWGV1W0GQR1XS
JVM-3	Mlm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXz3S\|E3UUN3ME2wMlY{QDB2IN88US=>	NGPLNopUSU6JRWK=
SF268	NFvnO5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIK0TYxKSzVyPUCuOlQ{PDlizszN	NV[1TWFLW0GQR1XS
OCI-AML2	NETJeFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnkemVKSzVyPUCuOlU{QTdizszN	NXrtfJFjW0GQR1XS
RPMI-8226	MkfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLCPXBKSzVyPUCuOlY{OjNizszN	NUfxR29VW0GQR1XS
MKN28	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHOyeGNKSzVyPUCuOlY3OjRizszN	NELSO\|VUSU6JRWK=
MDA-MB-453	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDPV41KSzVyPUCuOlcyQCEQvF2=	MY\TRW5ITVJ?
BV-173	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DXbGlEPTB;MD62PFY4QSEQvF2=	NGPNSYpUSU6JRWK=
NCI-H358	MlXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPjTWM2OD1yLk[4O\|I3KM7:TR?=	M1HiSnNCVkeHUh?=
NCI-H1651	NYW5UJBPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\0TWM2OD1yLkeg{txO	NWTGOoFuW0GQR1XS
MDA-MB-415	NVPxUGZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjJNYxKSzVyPUCuO\|A5OjlizszN	MoSzV2FPT0WU
8305C	NXywdmNoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInsbIVKSzVyPUCuO\|I1QThizszN	NG\Ybm1USU6JRWK=
EFM-19	M1vOT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnkTWM2OD1yLkezOlcyKM7:TR?=	MYHTRW5ITVJ?
RERF-LC-MS	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkGzTWM2OD1yLke0OlE{KM7:TR?=	MofCV2FPT0WU
A388	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jBPWlEPTB;MD63OlQ3PyEQvF2=	MV7TRW5ITVJ?
GI-ME-N	NEi5WXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknkTWM2OD1yLke3NlM2KM7:TR?=	NYHMRlU1W0GQR1XS
IGR-1	NV;qW3BZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTBwN{mwOFMh\|ryP	MV3TRW5ITVJ?
LNCaP-Clone-FGC	MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDoXGZxUUN3ME2wMlgxODB2IN88US=>	NFq2WI1USU6JRWK=
SK-MEL-3	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTBwOEG1NFgh\|ryP	M2jyRXNCVkeHUh?=
UACC-257	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTlbGhlUUN3ME2wMlgzOjNzIN88US=>	NGrTXIxUSU6JRWK=
OE33	MmTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmq1TWM2OD1yLki1NVAyKM7:TR?=	MmDUV2FPT0WU
QIMR-WIL	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETTbIRKSzVyPUCuPFUyPDFizszN	M1z4R3NCVkeHUh?=
NCI-H2009	NXfjbVE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfZeFZoUUN3ME2wMlg2OzFzIN88US=>	NVjGTZpIW0GQR1XS
NCI-H522	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHOTWM2OD1yLki3O\|g{KM7:TR?=	NGHqfXVUSU6JRWK=
Saos-2	NF3YdGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzxTWM2OD1yLki3PFcyKM7:TR?=	MVTTRW5ITVJ?
NB17	M{W2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{WwOmlEPTB;MD64PFAzPSEQvF2=	NG\i[W5USU6JRWK=
D-392MG	NICwd2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvnbZZFUUN3ME2wMlg6OzV4IN88US=>	NGqyd\|JUSU6JRWK=
SHP-77	M1zjZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTSfm9KSzVyPUCuPVA1QDVizszN	MlnIV2FPT0WU
SK-MEL-30	NUnlWHZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfhWG9KSzVyPUCuPVEyQDVizszN	M4jKcnNCVkeHUh?=
GCIY	M1;GO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TIO2lEPTB;MD65NVg1OyEQvF2=	MV7TRW5ITVJ?
HCC70	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzxUm1KSzVyPUCuPVIxPTlizszN	MUTTRW5ITVJ?
LU-65	NYnYSFZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjpeJhqUUN3ME2wMlkzPTlzIN88US=>	NWD6W\|lMW0GQR1XS
NCI-H1563	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfINVVKSzVyPUCuPVQ5PjVizszN	Mk\KV2FPT0WU
KURAMOCHI	M3r0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjEeHRKSzVyPUCuPVUyQTJizszN	MYrTRW5ITVJ?
PA-1	M{PIOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTvcWs4UUN3ME2wMlk2PDJ2IN88US=>	M{LzOHNCVkeHUh?=
NOS-1	NFPIeHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTBwOUe0PFkh\|ryP	NEfrVXBUSU6JRWK=
NCI-H69	NHOzR5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXP2S45iUUN3ME2wMlk4PjN2IN88US=>	MmTVV2FPT0WU
KYSE-450	NIi2RYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjaZm5IUUN3ME2wMlk5PjJ4IN88US=>	MmrmV2FPT0WU
8505C	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHmWnliUUN3ME2wMlk6QTh{IN88US=>	NFH5[2JUSU6JRWK=
TGBC24TKB	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXUTWM2OD1zLkCwNFg1KM7:TR?=	M3XjOHNCVkeHUh?=
PFSK-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\tRWJVUUN3ME2xMlAyPDJ6IN88US=>	NV7pclB5W0GQR1XS
EKVX	NEXZNYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3m4fGlEPTB;MT6wN\|EzOSEQvF2=	NWfGWlVDW0GQR1XS
RCM-1	M4nSdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4n1fWlEPTB;MT6wOVUxPyEQvF2=	MUHTRW5ITVJ?
SW900	NXTpb2JOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTFwMEe4N{DPxE1?	NYOy[YNvW0GQR1XS
D-542MG	M2[wbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnn3TWM2OD1zLkC3PFU2KM7:TR?=	NWKxNGllW0GQR1XS
SK-PN-DW	MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;DZ2lEPTB;MT6xNFA2PiEQvF2=	Mor2V2FPT0WU
NCI-H727	MmjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4Wxc2lEPTB;MT6xNFE2PCEQvF2=	NYDSe3VlW0GQR1XS
SW837	NFSwb\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfETWM2OD1zLkGwPVU1KM7:TR?=	NVLuN3VkW0GQR1XS
BT-20	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWSxOVFuUUN3ME2xMlEyOjB2IN88US=>	MonKV2FPT0WU
RH-18	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTFwMUOxNFMh\|ryP	Mn;uV2FPT0WU
TE-12	MnTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTFwMUOzN\|Mh\|ryP	Mnz3V2FPT0WU
NB10	NXuyNVhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfIV3h[UUN3ME2xMlE{OzR2IN88US=>	NU\rVYpEW0GQR1XS
AU565	M3u0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVrMUVF7UUN3ME2xMlE2QTd\|IN88US=>	NIn5WGpUSU6JRWK=
OAW-42	M2X5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3e0VGlEPTB;MT6xPFMxPiEQvF2=	MmHBV2FPT0WU
DJM-1	NVrkUo9kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjQc2EyUUN3ME2xMlE6QDhzIN88US=>	NE[0WXVUSU6JRWK=
HH	MljmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTFwMkO4N\|Eh\|ryP	NHjaOGdUSU6JRWK=
LAMA-84	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTFwMkezPVQh\|ryP	NWe4bnBUW0GQR1XS
KNS-42	NFHxWFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTFwM{CyPVYh\|ryP	NHrsOpNUSU6JRWK=
NCI-H2052	NHfvfVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTFwM{C1NFch\|ryP	MWDTRW5ITVJ?
MLMA	NHzmZm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPrTWM2OD1zLkOyOFA4KM7:TR?=	NY\SUmVLW0GQR1XS
NB12	M3fodWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\mO45xUUN3ME2xMlM2PjN4IN88US=>	NWq4[\|R4W0GQR1XS
NCI-H1838	NY\jeld1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTFwM{[zNFYh\|ryP	NHXs[m1USU6JRWK=
NCI-H526	M1;Fdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPlblYxUUN3ME2xMlM4QDV\|IN88US=>	NGToNJZUSU6JRWK=
LS-123	NUfuRmdOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTFwM{mwPVQh\|ryP	M4XMPHNCVkeHUh?=
HDLM-2	NXjxOlV3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NET3XVZKSzVyPUGuN\|kzPzFizszN	MkPpV2FPT0WU
MC-IXC	M3roW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\FT\|FKSzVyPUGuOFI{PzFizszN	MoDmV2FPT0WU
HCT-15	MmLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTFwNEOwOlgh\|ryP	NF7VNmJUSU6JRWK=
NCI-H596	NFHzXJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\ofGlEPTB;MT60OVA3OSEQvF2=	MXPTRW5ITVJ?
ZR-75-30	NV3NdphVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLtOXc2UUN3ME2xMlQ4ODh{IN88US=>	NVGxe2lwW0GQR1XS
A704	MnzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTRWnZqUUN3ME2xMlY3PTZ\|IN88US=>	Mo\UV2FPT0WU
OVCAR-4	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jaR2lEPTB;MT62PVYxPyEQvF2=	MX7TRW5ITVJ?
SW1417	NVj0fZR3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XD[GlEPTB;MT63Nlg1QSEQvF2=	NEn5WW1USU6JRWK=
CAS-1	NHrWcGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUe1XIg4UUN3ME2xMlc{QTN4IN88US=>	NUjw[JduW0GQR1XS
IST-SL1	MoPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmj4TWM2OD1zLke5O\|U6KM7:TR?=	Mne3V2FPT0WU
A253	M1GwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37hXWlEPTB;MT64NlI{QSEQvF2=	NY\2cVhvW0GQR1XS
EW-16	M4L4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTFwOEK4O\|Uh\|ryP	MmfBV2FPT0WU
SK-NEP-1	NVz2cIdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorDTWM2OD1zLki2PVg5KM7:TR?=	NIPBN5JUSU6JRWK=
NCI-H226	NGjhVYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTFwOEmzOVkh\|ryP	M4S4WXNCVkeHUh?=
HOP-92	M4rmSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LyZmlEPTB;MT65OlA6QSEQvF2=	M3zkPXNCVkeHUh?=
NCI-H441	M{D6V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrXRVVKSzVyPUKuNFI{OzdizszN	NEXjNWpUSU6JRWK=
LU-139	NXr3[nZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPUVohiUUN3ME2yMlA{OTF2IN88US=>	NYO1bZo3W0GQR1XS
SJRH30	MnzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTJwMESyOVMh\|ryP	M4TLZ3NCVkeHUh?=
MG-63	NX3aZ3ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DhWmlEPTB;Mj6xOFEyOSEQvF2=	MojrV2FPT0WU
NH-12	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF23eXhKSzVyPUKuNVUxODZizszN	NVnmNodrW0GQR1XS
NB7	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTzTWM2OD1{LkG5Olc{KM7:TR?=	M4rH[3NCVkeHUh?=
LB771-HNC	NITOU\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{X2VWlEPTB;Mj6yNFU6PSEQvF2=	MkXxV2FPT0WU
HCC1569	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTJwMkS1PFMh\|ryP	MXzTRW5ITVJ?
D-283MED	MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfZZ49KSzVyPUKuNlQ4QDJizszN	NHHTcWNUSU6JRWK=
J-RT3-T3-5	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjpR5NFUUN3ME2yMlI2OzVzIN88US=>	NGfVWHJUSU6JRWK=
ATN-1	NV:yRopXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vPSWlEPTB;Mj6zN\|A5OiEQvF2=	NEnxTnBUSU6JRWK=
HCC1954	NIPtN3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlmwTWM2OD1{LkO0OFA5KM7:TR?=	MoXyV2FPT0WU
SCC-15	NEPmZYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XjbmlEPTB;Mj6zPVMyOiEQvF2=	NVnze4RKW0GQR1XS
COLO-668	MnzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTJwNEOyJO69VQ>?	MWjTRW5ITVJ?
LB373-MEL-D	NWKxSpROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\0cGlEPTB;Mj61OFY4PyEQvF2=	NXzYWW5QW0GQR1XS
no-10	NVzYPGtLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\IeHJEUUN3ME2yMlU1QTR5IN88US=>	NH33dmhUSU6JRWK=
HT-1197	NULVSYZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\JSJE{UUN3ME2yMlY{OTh6IN88US=>	NUXSV2R5W0GQR1XS
DU-145	NF3zcHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTJwN{mxOlIh\|ryP	MnrZV2FPT0WU
SK-N-AS	M1\xZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfmTWM2OD1{Lki0OlkzKM7:TR?=	NWnBOYpOW0GQR1XS
MOLT-4	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTJwOEWzNlIh\|ryP	NWfN[G1YW0GQR1XS
EW-22	MnP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGD2VJJKSzVyPUKuPVI5PDFizszN	MkLWV2FPT0WU
DB	NFL0PIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfGNoxRUUN3ME2yMlk4PzV7IN88US=>	MnHyV2FPT0WU
HL-60	M2LnS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTNwMESzO\|Yh\|ryP	Mn\qV2FPT0WU
SK-N-DZ	M2K5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrhWXVKSzVyPUOuNFUxPzVizszN	M4j2VHNCVkeHUh?=
NY	M121S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17tSGlEPTB;Mz6wPFU1OiEQvF2=	MnXUV2FPT0WU
T47D	M3LwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDTTWM2OD1\|LkGwOVU5KM7:TR?=	Ml7tV2FPT0WU
NCI-H2029	NWLxcm1MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jFU2lEPTB;Mz6yNlQ4PyEQvF2=	MVPTRW5ITVJ?
KARPAS-299	M4Owc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFv6U2xKSzVyPUOuNlYxOjdizszN	MX3TRW5ITVJ?
KM-H2	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXj5R2RWUUN3ME2zMlMxPjhizszN	Mn\EV2FPT0WU
CHP-134	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHCXWFbUUN3ME2zMlQ4OzlizszN	MYLTRW5ITVJ?
22RV1	NUGyNpdOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\CcGtOUUN3ME2zMlQ6OTZ6IN88US=>	M1XnWHNCVkeHUh?=
NB5	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlq5TWM2OD1\|LkWwOlg6KM7:TR?=	NUn4bY01W0GQR1XS
CW-2	Moj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTNwNUWzNVQh\|ryP	MVHTRW5ITVJ?
EFO-21	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnKPFJKUUN3ME2zMlU3QTRizszN	M3nyW3NCVkeHUh?=
HuH-7	MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX2zNYNRUUN3ME2zMlU5PDF2IN88US=>	NIXKU\|JUSU6JRWK=
ALL-PO	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3:1VWlEPTB;Mz62NlM{PSEQvF2=	MkXwV2FPT0WU
EM-2	NHvFR3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XRTWlEPTB;Mz62PVAyOSEQvF2=	MUDTRW5ITVJ?
KLE	NUm5ZlRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;vV2lEPTB;Mz63N\|AzQSEQvF2=	MWjTRW5ITVJ?
NEC8	M{\iTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLIdG9xUUN3ME2zMlkyQDB6IN88US=>	NHPOUnVUSU6JRWK=
KP-N-YN	NYrYPXR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PkTWlEPTB;Mz65N\|Q4PiEQvF2=	MkjiV2FPT0WU
SK-MEL-1	MnzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTQW\|VKSzVyPUSuNFM2OThizszN	MVLTRW5ITVJ?
CAL-54	Mli5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfXSIZKSzVyPUSuNFU6OSEQvF2=	NWq4cFdVW0GQR1XS
MS-1	NUjlT2EzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TNRmlEPTB;ND6xOlE2PSEQvF2=	M1KxdnNCVkeHUh?=
NCI-H209	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHKzcolKSzVyPUSuNlk6QTlizszN	NULpZZh6W0GQR1XS
NOMO-1	NXLvSmRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTRwM{KxN\|Eh\|ryP	NIfDe2ZUSU6JRWK=
RPMI-2650	M{HaRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn[5TWM2OD12LkO2N\|I4KM7:TR?=	NHy4cmlUSU6JRWK=
NCI-H810	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTRwM{m3N\|Yh\|ryP	NWLDdldKW0GQR1XS
Ca9-22	M{jzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTRwNEW2PVEh\|ryP	MVzTRW5ITVJ?
ES4	Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLqTWM2OD12LkS3NFk2KM7:TR?=	Ml[zV2FPT0WU
ES6	M{\xeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTRwNEm2OVch\|ryP	NEHEOnVUSU6JRWK=
DMS-114	Mk\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\UTWM2OD12LkW0OlkyKM7:TR?=	M3zOUnNCVkeHUh?=
ONS-76	NFvuVHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTRwNUe5OUDPxE1?	Mn;3V2FPT0WU
K-562	NGLT[5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfYXpFoUUN3ME20Mlc{QDF2IN88US=>	NWH4S4FzW0GQR1XS
MHH-NB-11	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXHTWM2OD12Lke1OFYyKM7:TR?=	NXniNYFLW0GQR1XS
Calu-3	M4fDW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXjWGZKSzVyPUSuO\|g2PDhizszN	MlmwV2FPT0WU
HT55	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfvdmVYUUN3ME20Mlg1PTR3IN88US=>	NVzKZ5lsW0GQR1XS
SK-N-FI	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLlTWM2OD12Lki1NFA6KM7:TR?=	MWDTRW5ITVJ?
ES1	MlfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDGTWM2OD12Lki2NFU4KM7:TR?=	MorMV2FPT0WU
SF126	NWn0d4wyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnH5TWM2OD12LkmzNVg1KM7:TR?=	NIPLOplUSU6JRWK=
ES5	NFvyWWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnf5TWM2OD13LkGyOFI4KM7:TR?=	MkfLV2FPT0WU
LoVo	MlzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXObmZ2UUN3ME21MlE2QDdzIN88US=>	NHS0R\|BUSU6JRWK=
SNU-387	NHfBV21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHhendFUUN3ME21MlMzOzN7IN88US=>	MnHOV2FPT0WU
C8166	M{O1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnVXJJKSzVyPUWuN\|Y{OzlizszN	MW\TRW5ITVJ?
LS-1034	M3z4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHVcnJRUUN3ME21MlQzOzB5IN88US=>	M{DuVXNCVkeHUh?=
GR-ST	MnTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PBWGlEPTB;NT61NlIxOSEQvF2=	Mlf2V2FPT0WU
NCI-H1092	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnq2TWM2OD13LkeyPFQ{KM7:TR?=	MmLnV2FPT0WU
647-V	Mm\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTVwN{S3NFYh\|ryP	MUTTRW5ITVJ?
EW-13	NXz2O4dCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTVwN{[2Nlch\|ryP	M1TudHNCVkeHUh?=
KGN	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTZwMEm5NlEh\|ryP	M13aOHNCVkeHUh?=
D-423MG	NV7KW\|YyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTZwNECyPFQh\|ryP	MnPtV2FPT0WU
ECC10	NIj4dXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTdwMUCxNFEh\|ryP	MmnOV2FPT0WU
TE-5	M2Tpemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfLTWM2OD15LkSxNlk5KM7:TR?=	NGHVdVhUSU6JRWK=
P12-ICHIKAWA	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHL4d3BKSzVyPUeuOFU2OjNizszN	M2[5dHNCVkeHUh?=
NCI-H82	M3HnXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mln2TWM2OD15LkS1O\|AyKM7:TR?=	MoTJV2FPT0WU
NCI-H1993	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHyxS5lKSzVyPUeuPFMxPjNizszN	NXj5N4tiW0GQR1XS
RH-1	NHTkXndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIX4R2xKSzVyPUeuPFUzPDRizszN	NWXVZY5kW0GQR1XS
SW948	NVPUSlM4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\rcmlKSzVyPUeuPVYxPDlizszN	M1;GSHNCVkeHUh?=
CAL-33	Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTyc3RKSzVyPUeuPVk6OzhizszN	NGDMcpFUSU6JRWK=
U-266	M4LlSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlu4TWM2OD16LkG1O\|c4KM7:TR?=	MlHMV2FPT0WU
CAL-72	NEKwT\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXX3cWNZUUN3ME24MlIxOzJizszN	M4DtO3NCVkeHUh?=
SNU-423	NEmyfoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTlwM{[2OlYh\|ryP	M2O1VXNCVkeHUh?=
KG-1	M4PqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\1RmIxUUN3ME25MlU5PDV4IN88US=>	M1nkbnNCVkeHUh?=
HCC1395	NX\NOGh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfLXlFKSzVyPUmuPVI{PTJizszN	NFvCUWFUSU6JRWK=
BE-13	NWL6cnh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7KRnJKSzVyPUGwMlg5QTJizszN	MnPiV2FPT0WU
MKN7	M3rP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfhWphSUUN3ME2xNE46PzZ3IN88US=>	M2\3OXNCVkeHUh?=
697	M3vx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnFTWM2OD1zMT6xOFczKM7:TR?=	M1zaWXNCVkeHUh?=
LU-135	MmH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DSTmlEPTB;MUGuNlMxPyEQvF2=	NGLGbIJUSU6JRWK=
ES7	NF7HVGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTFzLkOzNVMh\|ryP	MXXTRW5ITVJ?
SK-HEP-1	MnPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TuSWlEPTB;MUGuO\|Y1PiEQvF2=	M{exeHNCVkeHUh?=
BEN	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;yTWM2OD1zMT64OVEh\|ryP	MVPTRW5ITVJ?
NCI-H1770	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fDXGlEPTB;MUKuNVI3KM7:TR?=	MWTTRW5ITVJ?
SW13	NGLp[IxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTF{LkG1OFEh\|ryP	MXXTRW5ITVJ?
MZ1-PC	MmDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17VSGlEPTB;MUKuOVQ2OiEQvF2=	NXHWRW4{W0GQR1XS
Mo-T	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIiwRlVKSzVyPUGyMlc1OjFizszN	M1nDTHNCVkeHUh?=
HLE	M4TBe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfQ[4pKUUN3ME2xNk45OjF3IN88US=>	NInQOYlUSU6JRWK=
RCC10RGB	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGntTFdKSzVyPUGzMlY4OSEQvF2=	NUKyVWpRW0GQR1XS
COLO-320-HSR	M1nIZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPmTWM2OD1zMz63N\|gyKM7:TR?=	NXL5e2huW0GQR1XS
BHT-101	M{TwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfrbmc4UUN3ME2xN{45OzR3IN88US=>	M1HSSXNCVkeHUh?=
OCUB-M	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLuN5hEUUN3ME2xOE4yPjB{IN88US=>	M1ziVHNCVkeHUh?=
MEG-01	MlvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PLVGlEPTB;MUSuN\|cxQCEQvF2=	M2Tj[XNCVkeHUh?=
RS4-11	NWDkeotIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXr5bVlFUUN3ME2xOE44PDJizszN	MlrxV2FPT0WU
MN-60	M{K2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4Lz[2lEPTB;MUSuO\|g6PCEQvF2=	NXqzb\|l2W0GQR1XS
NCI-H1304	M1ri[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTF3LkC0NlUh\|ryP	NWiybJFkW0GQR1XS
Ramos-2G6-4C10	MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF6wN2RKSzVyPUG1MlA2QDFizszN	NHLjR4ZUSU6JRWK=
NCI-H2342	NXjoNplMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTF3LkKwOFQh\|ryP	NEO1c3dUSU6JRWK=
LAN-6	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmP2TWM2OD1zNT60OFE1KM7:TR?=	NWL5OFlqW0GQR1XS
JVM-2	M2nZOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3S2XmlEPTB;MUWuOVc1QCEQvF2=	NWPzRmJ5W0GQR1XS
P30-OHK	M2rTcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTF4LkC2NVQh\|ryP	MoO0V2FPT0WU
C-33-A	M3q3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXiZlJVUUN3ME2xOk43OjF2IN88US=>	MXzTRW5ITVJ?
RPMI-8866	M1q2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PTVGlEPTB;MU[uPFQ6PiEQvF2=	NX3V[mdQW0GQR1XS
NCI-H630	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\sc21xUUN3ME2xOk45PTN5IN88US=>	MVXTRW5ITVJ?
KYSE-140	NVf0NHZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTF5LkKwNlgh\|ryP	MX;TRW5ITVJ?
T84	MlTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MknhTWM2OD1zOD64Olk2KM7:TR?=	M1;UXHNCVkeHUh?=
KU-19-19	M3nyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF32dWpKSzVyPUG4Mlk3ODhizszN	NHzPVoVUSU6JRWK=
BALL-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTF7LkOzPVkh\|ryP	NHnnN4lUSU6JRWK=
Calu-6	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vC[2lEPTB;MUmuOFkzKM7:TR?=	NXXiVZB2W0GQR1XS
EGI-1	NFjjR2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHPTWM2OD1zOT61PVgh\|ryP	NIjCPG5USU6JRWK=
MFH-ino	Mki0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLXbGJwUUN3ME2xPU44PDV2IN88US=>	NGrFSWZUSU6JRWK=
GB-1	NILHOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTJyLkO1N\|Uh\|ryP	MnXSV2FPT0WU
NCI-H1693	NEPsOFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEH1eYhKSzVyPUKwMlY2ODVizszN	MYjTRW5ITVJ?
SW1116	NHu5WppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3yzd2lEPTB;MkCuPVM3OiEQvF2=	M3PjOXNCVkeHUh?=
H-EMC-SS	NWL4TmhIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTJ{LkC0OUDPxE1?	M{PNU3NCVkeHUh?=
D-502MG	NFW5fJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnDZnJTUUN3ME2yNk45OjZzIN88US=>	Mk\rV2FPT0WU
IA-LM	M124OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTJ\|LkK0PVMh\|ryP	MUDTRW5ITVJ?
SW1463	M4L1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHNd3BSUUN3ME2yN{44QSEQvF2=	M1rEV3NCVkeHUh?=
JAR	MmC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoSzTWM2OD1{ND6zNlk{KM7:TR?=	M{HQWXNCVkeHUh?=
HT	NHvsTVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGS5d\|NKSzVyPUK0MlQ4PTNizszN	NWLtb2FHW0GQR1XS
LCLC-103H	NGO0OGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrzT3lKSzVyPUK0Mlg1PDlizszN	NULuTGVSW0GQR1XS
SNU-449	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTJ2Lki3OFEh\|ryP	MYnTRW5ITVJ?
KE-37	M{\1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFK2SJRKSzVyPUK1MlA6OjhizszN	NGfEflJUSU6JRWK=
NCI-H1623	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn73TWM2OD1{Nz6xN\|A{KM7:TR?=	M2jiXnNCVkeHUh?=
MOLT-13	MknLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17H[GlEPTB;MkeuN\|UyPiEQvF2=	NFTqWoJUSU6JRWK=
COLO-741	NYOyZndMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M162emlEPTB;M{GuN\|M{OyEQvF2=	NFL6W4ZUSU6JRWK=
NB6	MmXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvEfVZKSzVyPUOyMlI5PzZizszN	NWHhdVJqW0GQR1XS
MOLT-16	NUO3TpMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2ThUmlEPTB;M{OuNFA2PSEQvF2=	MnrsV2FPT0WU
IST-MES1	M1nPNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nGWmlEPTB;M{SuNFU1OSEQvF2=	NEXQ[m5USU6JRWK=
A4-Fuk	MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDnR\|BKSzVyPUO1MlA3PiEQvF2=	M120cnNCVkeHUh?=
CAL-85-1	Mmf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HKSWlEPTB;M{WuNlgyPyEQvF2=	NFP4OGpUSU6JRWK=
CCRF-CEM	MontS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTHTWM2OD1\|Nz6xOVM3KM7:TR?=	M4TtdnNCVkeHUh?=
HAL-01	M{jGNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvDVWVKSzVyPUO4MlQ5QDlizszN	NVPzfW5wW0GQR1XS
HEL	M1HpSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjXb2ZbUUN3ME20N{4{PDB7IN88US=>	M2\YSHNCVkeHUh?=
EW-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnwRYFYUUN3ME20N{41PzZ6IN88US=>	NIXJTldUSU6JRWK=
MDA-MB-231	MoHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYm0SYJ7UUN3ME20OU4yOTl7IN88US=>	NWjoOpJsW0GQR1XS
ABC-1	NWL2VmJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHu4bHRKSzVyPUS2Mlg2OzhizszN	MWHTRW5ITVJ?
NCI-H446	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTR6LkWwOVgh\|ryP	NVTOUoNiW0GQR1XS
MHH-PREB-1	M2[z[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4W4XmlEPTB;NEmuOlAxPyEQvF2=	MkTsV2FPT0WU
DOHH-2	NXzL[GdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTR7Lk[2OVYh\|ryP	MX3TRW5ITVJ?
GCT	NYnVPWZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTR7Lk[5O\|Yh\|ryP	NF7DXHVUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo

17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. ^[1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. ^[2]

Protocol

Kinase Assay:^[1]	+ Expand Hsp90 binding assays: Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl₂, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:^[1]	+ Expand Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 5 days Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A₄₉₀) of wells not containing cells is subtracted. Percentage of viable cells = (A₄₉₀ of 17-AAG treated sample/A₄₉₀ untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number. (Only for Reference)
Animal Research:^[2]	+ Expand Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6 Formulation: Dissolved in DMSO, and diluted in egg phospholipids (EPL) vehicle Dosages: ~50 mg/kg Administration: Injection i.p. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (170.73 mM)
	Ethanol	5 mg/mL (8.53 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+corn oil For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Tanespimycin (17-AAG) SDF

Molecular Weight	585.69
Formula	C₃₁H₄₃N₃O₈
CAS No.	75747-14-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	CP127374,NSC-330507, KOS 953

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00577889	Completed	Adenocarcinoma of the Pancreas\|Recurrent Pancreatic Cancer\|Stage IV Pancreatic Cancer	National Cancer Institute (NCI)	March 2008	Phase 2
NCT00577889	Completed	Adenocarcinoma of the Pancreas\|Recurrent Pancreatic Cancer\|Stage IV Pancreatic Cancer	National Cancer Institute (NCI)	March 2008	Phase 2
NCT00546780	Completed	Multiple Myeloma	Bristol-Myers Squibb	February 2008	Phase 3
NCT00546780	Completed	Multiple Myeloma	Bristol-Myers Squibb	February 2008	Phase 3
NCT00093496	Completed	Primary Peritoneal Cavity Cancer\|Recurrent Ovarian Epithelial Cancer\|Stage III Ovarian Epithelial Cancer\|Stage IV Ovarian Epithelial Cancer	National Cancer Institute (NCI)	October 2007	Phase 2
NCT00093496	Completed	Primary Peritoneal Cavity Cancer\|Recurrent Ovarian Epithelial Cancer\|Stage III Ovarian Epithelial Cancer\|Stage IV Ovarian Epithelial Cancer	National Cancer Institute (NCI)	October 2007	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?
Answer:
17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Selective HSP90 Inhibitor

NVP-BEP800 : HSP90β-selective, IC50=58 nM.
Most Potent HSP90 Inhibitor

KW-2478 : HSP90, IC50=3.8 nM.
HSP90 Inhibitor in Clinical Trial

17-DMAG (Alvespimycin) HCl : Phase II for Kidney Cancer.
Newest HSP90 Inhibitor

XL888 : ATP-competitive inhibitor of HSP90 with IC50 of 24 nM.

Related HSP (e.g. HSP90) Products4

PU-H71 ^New

PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90.
Luminespib (AUY-922, NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Phase 2.
Ganetespib (STA-9090)

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.
HSP990 (NVP-HSP990)

NVP-HSP990 (HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Elesclomol (STA-4783)

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Tanespimycin (17-AAG)

Cited by 24 Publications

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tanespimycin (17-AAG) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products4

Choose Your Country or Region

By Signaling Pathways

By product type

Tanespimycin (17-AAG)

Cited by 24 Publications

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tanespimycin (17-AAG) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)